Houston, Texas, United States, November 19, 2026
Marker Therapeutics, Inc. has been awarded a $16.2 million Product Development Research grant from the Cancer Prevention and Research Institute of Texas (CPRIT) to advance its investigational cell therapy MT-601 (neldaleucel) into a planned Phase II clinical study. The funding will support the development of MT-601 in patients with relapsed or refractory large B-cell lymphoma (LBCL) who have experienced disease progression following treatment with CD19-directed chimeric antigen receptor (CAR) T-cell therapy. The planned Phase II APOLLO study will build on earlier clinical findings and investigate the potential of Marker’s multi-antigen recognizing T-cell (MAR-T) platform in patients with limited treatment options. The award represents a significant development milestone for the Houston-based clinical-stage immuno-oncology company, providing substantial non-dilutive funding to support clinical development without requiring the issuance of additional company shares. CPRIT selected the project following a competitive review process that assessed scientific merit, clinical development strategy, regulatory considerations, manufacturing feasibility and commercial potential. The institute received 207 applications for this funding cycle and awarded a combined $74.3 million to 12 projects. The grant is expected to help Marker progress MT-601 through its next stage of clinical evaluation.
$16.2 Million CPRIT Grant Supports Phase II APOLLO Study
The CPRIT grant will provide financial support for the planned Phase II development of MT-601 in patients with CAR-T-relapsed large B-cell lymphoma. Despite advances in cancer immunotherapy, patients whose disease returns or progresses after CD19-directed CAR-T treatment continue to face significant therapeutic challenges. Some patients also have limited options after receiving multiple previous treatments, including bispecific antibody therapies. The planned APOLLO programme aims to evaluate whether MT-601 can offer another treatment approach for this difficult-to-treat population. The funding builds on earlier support received by Marker from the National Institutes of Health (NIH) Small Business Innovation Research programme, which contributed to the Phase I clinical development of MT-601. According to the company, the CPRIT award underwent independent scientific, clinical and commercial assessment, providing external recognition of the programme’s development potential. Marker expects to use the funding to advance the clinical programme and generate additional evidence regarding the therapy’s safety, clinical activity and durability of response. The company also indicated that updated clinical results and additional patient data are expected later in 2026.
MT-601 Targets Six Tumour-Associated Antigens
MT-601 (neldaleucel) is an investigational multi-antigen recognizing T-cell therapy designed to target six tumour-associated antigens expressed in lymphoma cells: Survivin, PRAME, WT-1, NY-ESO-1, SSX-2 and MAGEA-4. The therapy uses Marker’s proprietary MAR-T cell platform, which expands tumour-specific T cells capable of recognising multiple cancer-associated targets. Unlike genetically engineered CAR-T therapies, MT-601 uses a non-genetically modified approach to generate T cells with the ability to recognise several tumour antigens. Targeting multiple antigens may help address one of the challenges associated with single-target cancer therapies: tumour cells can sometimes escape treatment by reducing or losing expression of the specific antigen being targeted. By recognising multiple antigens, MAR-T cells are designed to reduce the likelihood of this type of tumour escape. The platform can recognise multiple epitopes across its targeted antigens, potentially enabling a broader immune response against malignant cells. Marker is developing MT-601 under an exclusive worldwide licence from Baylor College of Medicine. The company is investigating the therapy in patients with lymphoma who have relapsed following anti-CD19 CAR-T treatment or are not candidates for this treatment approach.
Phase I Results Support Further Clinical Investigation
The planned Phase II programme builds on findings from the Phase I APOLLO study, which evaluated MT-601 in heavily pretreated patients with non-Hodgkin lymphoma. In August 2025, Marker reported an objective response rate of 66% and a complete response rate of 50% among 12 evaluable patients. The company also reported durable responses, including responses lasting up to 24 months at the time of the data cutoff. MT-601 demonstrated a favourable safety profile across the evaluated dose levels, with no dose-limiting toxicities or cases of immune effector cell-associated neurotoxicity syndrome (ICANS) reported in the study. These early findings provide a clinical basis for further evaluation, although the small patient population means that larger studies are necessary to confirm the results. The planned Phase II APOLLO study will focus on determining whether the observed clinical activity can be reproduced in a broader patient population and provide additional information about response durability and safety. Marker aims to develop MT-601 as a potential treatment option for patients with relapsed or refractory lymphoma, particularly those whose disease has progressed after CAR-T therapy. MT-601 remains investigational and has not received regulatory approval. The CPRIT funding represents an important step in supporting its continued clinical development and advancing research into multi-antigen-targeted cancer immunotherapies.
Source: Marker Therapeutics press release



